News
First dose administration of glepaglutide in Phase III EASE-SBS 4 trial to treat short bowel syndrome.
Zealand Pharma A/S announced dose administration for the first subject in the Phase IIIb trial, EASE-SBS 4, evaluating glepaglutide , the company’s long-acting GLP-2 analog, which is being investigated as a potential treatment option for short bowel syndrome (SBS).
EASE-SBS 4 is an open-label single-center Phase IIIb trial investigating the long-term effect on intestinal absorption, nutritional status and long-term safety of administration of glepaglutide in patients with short bowel syndrome (SBS.)
Condition: Short Bowel Syndrome
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.